The	0	3	O
differential	4	16	O
regulation	17	27	O
of	28	30	O
human	31	36	B-Organism
telomerase	37	47	B-Gene_or_gene_product
reverse	48	55	I-Gene_or_gene_product
transcriptase	56	69	I-Gene_or_gene_product
and	70	73	O
vascular	74	82	B-Gene_or_gene_product
endothelial	83	94	I-Gene_or_gene_product
growth	95	101	I-Gene_or_gene_product
factor	102	108	I-Gene_or_gene_product
may	109	112	O
contribute	113	123	O
to	124	126	O
the	127	130	O
clinically	131	141	O
more	142	146	O
aggressive	147	157	O
behavior	158	166	O
of	167	169	O
p63	170	173	B-Gene_or_gene_product
-	173	174	O
positive	174	182	O
breast	183	189	O
carcinomas	190	200	O
.	200	201	O

p63	203	206	B-Gene_or_gene_product
,	206	207	O
a	208	209	O
p53	210	213	B-Gene_or_gene_product
homologue	214	223	O
,	223	224	O
is	225	227	O
a	228	229	O
myoepithelial	230	243	B-Cell
cell	244	248	I-Cell
marker	249	255	O
in	256	258	O
the	259	262	O
normal	263	269	O
mammary	270	277	B-Organ
gland	278	283	I-Organ
but	284	287	O
p63	288	291	B-Gene_or_gene_product
-	291	292	O
positive	292	300	O
neoplastic	301	311	O
cells	312	317	O
may	318	321	O
be	322	324	O
found	325	330	O
in	331	333	O
up	334	336	O
to	337	339	O
11	340	342	O
%	342	343	O
of	344	346	O
invasive	347	355	B-Pathological_formation
breast	356	362	I-Pathological_formation
carcinomas	363	373	I-Pathological_formation
.	373	374	O

This	375	379	O
study	380	385	O
aims	386	390	O
to	391	393	O
verify	394	400	O
the	401	404	O
relationship	405	417	O
between	418	425	O
p63	426	429	B-Gene_or_gene_product
expression	430	440	O
and	441	444	O
several	445	452	O
clinicopathological	453	472	O
features	473	481	O
and	482	485	O
tumor	486	491	B-Pathological_formation
markers	492	499	O
of	500	502	O
clinical	503	511	O
significance	512	524	O
in	525	527	O
breast	528	534	B-Organism_subdivision
pathology	535	544	O
including	545	554	O
key	555	558	O
regulators	559	569	O
of	570	572	O
the	573	576	O
cell	577	581	B-Cell
cycle	582	587	O
,	587	588	O
oncogenes	589	598	O
,	598	599	O
apoptosis	600	609	O
-	609	610	O
related	610	617	O
proteins	618	626	O
,	626	627	O
metalloproteinases	628	646	B-Gene_or_gene_product
and	647	650	O
their	651	656	O
inhibitors	657	667	O
.	667	668	O

Immunohistochemistry	669	689	O
with	690	694	O
27	695	697	O
primary	698	705	O
antibodies	706	716	O
was	717	720	O
performed	721	730	O
in	731	733	O
100	734	737	O
formalin	738	746	O
-	746	747	O
fixed	747	752	O
paraffin	753	761	O
-	761	762	O
embedded	762	770	O
samples	771	778	O
of	779	781	O
invasive	782	790	B-Pathological_formation
ductal	791	797	I-Pathological_formation
carcinomas	798	808	I-Pathological_formation
.	808	809	O

p63	810	813	B-Gene_or_gene_product
-	813	814	O
positive	814	822	O
cells	823	828	O
were	829	833	O
found	834	839	O
in	840	842	O
16	843	845	O
%	845	846	O
of	847	849	O
carcinomas	850	860	B-Pathological_formation
.	860	861	O

p63	862	865	B-Gene_or_gene_product
-	865	866	O
positive	866	874	O
carcinomas	875	885	O
were	886	890	O
poorly	891	897	O
differentiated	898	912	O
,	912	913	O
hormone	914	921	O
receptor	922	930	O
-	930	931	O
negative	931	939	O
neoplasms	940	949	B-Pathological_formation
with	950	954	O
a	955	956	O
high	957	961	O
proliferation	962	975	O
rate	976	980	O
.	980	981	O

p63	982	985	B-Gene_or_gene_product
also	986	990	O
correlated	991	1001	O
with	1002	1006	O
advanced	1007	1015	O
pathological	1016	1028	O
stage	1029	1034	O
,	1034	1035	O
tumor	1036	1041	B-Pathological_formation
size	1042	1046	O
,	1046	1047	O
and	1048	1051	O
the	1052	1055	O
expression	1056	1066	O
of	1067	1069	O
human	1070	1075	B-Organism
telomerase	1076	1086	B-Gene_or_gene_product
reverse	1087	1094	I-Gene_or_gene_product
transcriptase	1095	1108	I-Gene_or_gene_product
(	1109	1110	O
hTERT	1110	1115	B-Gene_or_gene_product
)	1115	1116	O
,	1116	1117	O
tissue	1118	1124	B-Gene_or_gene_product
inhibitor	1125	1134	I-Gene_or_gene_product
of	1135	1137	I-Gene_or_gene_product
matrix	1138	1144	I-Gene_or_gene_product
metalloproteinase	1145	1162	I-Gene_or_gene_product
1	1163	1164	I-Gene_or_gene_product
(	1165	1166	O
TIMP1	1166	1171	B-Gene_or_gene_product
)	1171	1172	O
and	1173	1176	O
vascular	1177	1185	B-Gene_or_gene_product
endothelial	1186	1197	I-Gene_or_gene_product
growth	1198	1204	I-Gene_or_gene_product
factor	1205	1211	I-Gene_or_gene_product
(	1212	1213	O
VEGF	1213	1217	B-Gene_or_gene_product
)	1217	1218	O
.	1218	1219	O

The	1220	1223	O
expression	1224	1234	O
of	1235	1237	O
TIMP1	1238	1243	B-Gene_or_gene_product
suggests	1244	1252	O
that	1253	1257	O
the	1258	1261	O
anti	1262	1266	O
-	1266	1267	O
proteolytic	1267	1278	O
stimuli	1279	1286	O
may	1287	1290	O
be	1291	1293	O
preponderant	1294	1306	O
in	1307	1309	O
p63	1310	1313	B-Gene_or_gene_product
-	1313	1314	O
positive	1314	1322	O
carcinomas	1323	1333	O
.	1333	1334	O

hTERT	1335	1340	B-Gene_or_gene_product
activity	1341	1349	O
is	1350	1352	O
associated	1353	1363	O
with	1364	1368	O
nodal	1369	1374	O
metastases	1375	1385	O
and	1386	1389	O
cellular	1390	1398	O
proliferation	1399	1412	O
.	1412	1413	O

VEGF	1414	1418	B-Gene_or_gene_product
regulates	1419	1428	O
angiogenesis	1429	1441	O
,	1441	1442	O
which	1443	1448	O
is	1449	1451	O
also	1452	1456	O
a	1457	1458	O
fundamental	1459	1470	O
event	1471	1476	O
in	1477	1479	O
the	1480	1483	O
process	1484	1491	O
of	1492	1494	O
tumor	1495	1500	B-Pathological_formation
growth	1501	1507	O
and	1508	1511	O
metastatic	1512	1522	O
dissemination	1523	1536	O
.	1536	1537	O

Thus	1538	1542	O
,	1542	1543	O
the	1544	1547	O
differential	1548	1560	O
regulation	1561	1571	O
of	1572	1574	O
hTERT	1575	1580	B-Gene_or_gene_product
and	1581	1584	O
VEGF	1585	1589	B-Gene_or_gene_product
in	1590	1592	O
p63	1593	1596	B-Gene_or_gene_product
-	1596	1597	O
positive	1597	1605	O
breast	1606	1612	O
carcinomas	1613	1623	O
may	1624	1627	O
contribute	1628	1638	O
to	1639	1641	O
the	1642	1645	O
clinically	1646	1656	O
more	1657	1661	O
aggressive	1662	1672	O
behavior	1673	1681	O
of	1682	1684	O
these	1685	1690	O
neoplasms	1691	1700	B-Pathological_formation
.	1700	1701	O

